Clinical Trial Detail

NCT ID NCT03220477
Title Pembrolizumab (Immunotherapy Drug) in Combination With Guadecitabine and Mocetinostat (Epigenetic Drugs) for Patients With Advanced Lung Cancer.
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements yes
Sponsors Memorial Sloan Kettering Cancer Center
Indications

lung non-small cell carcinoma

Therapies

Guadecitabine + Mocetinostat + Pembrolizumab

Age Groups: adult senior

Additional content available in CKB BOOST